¿¬±¸µ¿Ç⠺м® : ¾ÆÅä¹Ù½ºÅ¸Æ¾ÀÇ »õ·Î¿î ¾à¹° ÀûÀÀÁõ Ž»öÀ» À§ÇÑ ÅؽºÆ® ¸¶ÀÌ´× ºÐ¼®
¹è°æ : ¸Å³â ¸¹Àº ÀÇÇבּ¸°¡ ÃâÆǵǰí ÀÖ´Â ¿äÁò, º¸°ÇÀÇ·áÀεéÀº Áø·á¿¡ µµ¿òÀÌ µÇ´Â »õ·Î¿î Á¤º¸¸¦ ¾ò±â À§ÇÑ ´É·ÂÀ» ¿ä±¸¹Þ°í ÀÖÀ¸¸ç, ü°èÀû ¹®Çå°íÂûÀ̳ª ¸ÞŸ ºÐ¼® µî°ú °°ÀÌ ¿¬±¸°á°úµéÀ» ü°èÀûÀ¸·Î Á¤¸®ÇÏ¿© °á·Ð ³»´Â ¹æ¹ýµéµµ °³¹ßµÇ¾ú´Ù. ¶ÇÇÑ ÀÓ»ó¹®ÇåÀ¸·ÎºÎÅÍ ¿øÇÏ´Â Áö½ÄÀ» ÃßÃâÇÏ´Â ¹æ¹ý¿¡¼µµ µ¥ÀÌÅÍ ¸¶ÀÌ´×(data mining) ±â¹ý µî ÀÌ °í·ÁµÇ¾ú´Ù.
º» ¿¬±¸¿¡¼´Â ½É³úÇ÷°ü ÁúȯÀÇ ÁÖ¿ä À§ÇèÀÎÀÚÀÎ °íÁöÇ÷Áõ Ä¡·áÁ¦ÀÎ ÇÏÀ̵å·Ï½Ã ¸ÞÆ¿±Û·çŸ¸± Á¶È¿¼ÒA (Hydroxy-methylglutaryl Coenzyme A, HMG-CoA)ȯ¿øÈ¿¼Ò ¾ïÁ¦Á¦µé Áß ¾ÆÅä¹Ù½ºÅ¸
ƾ(Atorvastatin; Lipitor¨Þ, Pfizer, Inc., New York, USA)ÀÇ ÀÇÇÐ³í¹®Á¤º¸¸¦ ÀÌ¿ëÇÏ¿´´Âµ¥ HMG-CoA ȯ¿øÈ¿¼Ò ¾ïÁ¦Á¦ Á¦Ç° Áß ¾ÆÅä¹Ù½ºÅ¸Æ¾ÀÌ ±¹³»¸¦ ºñ·ÔÇÏ¿© Àü ¼¼°èÀûÀ¸·Î ¸¹ÀÌ Ã³¹æµÇ°í ÀÖÀ¸¸ç 2008³â¿¡´Â´ç´¢º´ ¹ß»ýÀÇ ºÎÀÛ¿ëÀÌ º¸°íµÈ ÀÌÈÄ Àå±â°£ »ç¿ë¿¡ ´ëÇØ ³í¶õ ÁßÀ̱⠶§¹®ÀÌ´Ù.
¿¬±¸ÀÚ·á : ¹Ì±¹ ±¹¸³º¸°Ç¿øÀÇ PubMed¸¦ ÀÌ¿ëÇÏ¿© Medline µ¥ÀÌÅͺ£À̽º¿¡ ÀÖ´Â ¾ÆÅä¹Ù½ºÅ¸Æ¾ °ü·Ã ¿¬±¸³í¹® 5,057Æí ÃßÃâ. º» ¿¬±¸´Â 5,057ÆíÀÇ ¾ÆÅä¹Ù½ºÅ¸Æ¾ ¿¬±¸ÃÊ·ÏÀ» ÀÌ¿ëÇÏ¿© ³Ý¸¶ÀÌ³Ê 4.0 (Netminer, Cyram Inc., Seoul, Korea) ÇÁ·Î±×·¥À» ÀÌ¿ëÇÏ¿© ºÐ¼® ÇÔ
¿¬±¸ÃʷϵéÀÇ ÀϹÝÀû Ư¼º ¹× ÅؽºÆ® ¸¶ÀÌ´× °á°ú : ÃÑ 5,057°³ÀÇ ¾ÆÅä¹Ù½ºÅ¸Æ¾ ¿¬±¸ ³í¹® ÃʷϵéÀº 1990³â ÃâÆÇÀ» ½Ã ÀÛÀ¸·Î 2005³âºÎÅÍ 2015³â±îÁö ¸Å³â 300Æí ÀÌ»óÀÌ ¹ßÇ¥µÇ¾úÀ¸¸ç 2018 ³â¿¡´Â 217ÆíÀÌ º¸°íµÇ¾ú´Ù. Ãʷϵ鿡¼ ÃßÃâµÈ 273°³ÀÇ Áúº´ Å°¿öµåµé Áß ÃÑ 2,008¹ø ÃâÇöÇÑ ´ç´¢º´(Diabetes mellitus)À» Æ÷ÇÔÇÏ¿© ÃâÇö ºóµµ »óÀ§ 10À§ÀÎ Áúº´ Å°¿öµåµé·Î´Â ½ÉÇ÷°ü Áúȯ(Cardiovascular disease), °ü»óµ¿¸ÆÁúȯ(Coronary artery disease), ±Þ¼º °ü»óµ¿¸Æ ÁõÈÄ ±º(Acute coronary syndrome), °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ(Hypercholesterolemia), ³úÁ¹Áß(Stroke), ½É±Ù°æ»öÁõ(Myocardial infarction), ÀÌ»óÁöÁúÇ÷ Áõ(Dyslipidemia), Á×»ó°æÈÁõ(Atherosclerosis), °íÇ÷¾Ð(Hypertension)À̾ú´Ù.
Year
|
1990
|
1995
|
1996
|
1997
|
1998
|
1999
|
2000
|
2001
|
2002
|
2003
|
2004
|
2005
|
n
|
1
|
4
|
9
|
20
|
41
|
47
|
99
|
129
|
158
|
238
|
255
|
334
|
%
|
0.02
|
0.08
|
0.18
|
0.40
|
0.81
|
0.93
|
1.96
|
2.55
|
3.12
|
4.70
|
5.04
|
6.60
|
Year
|
2006
|
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
2013
|
2014
|
2015
|
2016
|
2017
|
n
|
317
|
303
|
359
|
313
|
338
|
347
|
317
|
300
|
323
|
304
|
284
|
217
|
%
|
6.27
|
5.99
|
7.10
|
6.20
|
6.68
|
6.86
|
6.27
|
5.93
|
6.39
|
6.01
|
5.62
|
4.29
|
ÃâÇöºóµµ »óÀ§ 50À§ÀÎ Å°¿öµåµé·Î ±¸¼ºµÈ ³×Æ®¿öÅ© ºÐ¼® °á°ú : 273°³ÀÇ Å°¿öµåµé Áß ÃâÇöºóµµ »óÀ§ 50À§ÀÎ Å°¿öµåµé·Î ±¸¼ºµÈ ³×Æ®¿öÅ© ºÐ¼® °á°ú ¹Ðµµ´Â 0.09 (¹üÀ§ 0-1)À̾ú´Ù Á߽ɼº ºÐ¼®¿¡¼´Â ÇÑ Å°¿öµå°¡ ´Ù¸¥ Å°¿öµåµé°ú ¿¬°áµÈ Á¤µµ¸¦ ÀǹÌÇÏ´Â ¿¬°áÁ¤µµ Á߽ɼº °ªÀÇ Æò±ÕÀº 0.096±0.097 (¹üÀ§ 0-0.347)À̾úÀ¸¸ç, Á߽ɼº ôµµ(centrality index)´Â 26.2%À̾ú´Ù. ¿¬°áÁ¤µµ°¡ ³ôÀº »ó À§ 10À§ÀÇ Å°¿öµåµéÀº ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ÀÌ»óÁöÁúÇ÷Áõ, Á×»ó°æÈÁõ, °íÇ÷¾Ð, °ü»óµ¿¸ÆÁúȯ, ½É±Ù°æ»öÁõ, ½ÉÀå»ç°Ç ÈÄ ÁÖ¿äºÎÀÛ¿ë(major ad\-verse cardiac events), ±Þ¼º °ü»óµ¿¸Æ ÁõÈıº, ´ë»çÁõÈıº(Metabolic syndrome)À̾ú´Ù.
À̵é Áß TF-IDF Á¤µµ°ª(degree)ÀÇ »óÀ§ 10À§ÀÎ Å°¿öµåµéÀº ½É¹æ ¼¼µ¿(Atrial fibrilla\-tion), ½ÉºÎÀü(Heart failure), À¯¹æ¾Ï(Breast cancer), ·ù¸¶Æ¼½º °üÀý¿°, º¹ ÇÕ °íÁöÇ÷Áõ, ºÎÁ¤¸Æ(Arrhythmias), ´Ù¹ß¼º °æÈÁõ(Multiple sclerosis), ºñ¾ËÄݼº Áö¹æ°£¿°, Á¶¿µÁ¦ À¯¹ß ½Å¼Õ»ó, Àü¸³¼±¾Ï(Prostate cancer)À̾ú ´Ù´Ù¸¥ Å°¿öµåµé°ú °¡±î¿î °Å¸® ¿©ºÎ¸¦ È®ÀÎÇÏ´Â ±ÙÁ¢ Á߽ɼº °ªÀÇ Æò±ÕÀº 0.231±0.146 (¹üÀ§ 0-0.439)À̾ú°í Á߽ɼº ôµµ ´Â 24.7%À̾ú´Ù. ±ÙÁ¢ Á߽ɼº °ªÀÌ ³ôÀº »óÀ§ 10°³ÀÇ Áúº´ Å°¿öµåµéÀº ´ç´¢º´, ÀÌ»óÁöÁúÇ÷Áõ, ½ÉÇ÷°ü Áúȯ, °ü»óµ¿¸ÆÁúȯ, Á×»ó°æÈÁõ, °íÇ÷¾Ð, °íÄÝ·¹½ºÅ×·ÑÇ÷Áõ, ½É±Ù°æ»öÁõ, ½ÉÀå»ç°Ç ÈÄ ÁÖ¿äºÎÀÛ¿ë, °íÁöÇ÷Áõ ¼ø À̾ú´Ù.
No
|
Keywords by
degreecentrality
|
Score
|
Keywords by
dosenesscentrality
|
Score
|
1
|
Diabetes mellitus
|
0.346
|
Diabetes mellitus
|
0.438
|
2
|
CVD
|
0.306
|
Dyslipidemia
|
0.423
|
3
|
Dyslipidemia
|
0.286
|
CVD
|
0.423
|
4
|
Atherosclerosis
|
0.285
|
CAD
|
0.416
|
5
|
Hypertension
|
0.265
|
Atherosclerosis
|
0.409
|
6
|
CAD
|
0.265
|
Hypertension
|
0.403
|
7
|
Myocardial infarction
|
0.225
|
Hypercholesterolemia
|
0.384
|
8
|
MACE
|
0.224
|
Myocardial infarction
|
0.373
|
9
|
ACS
|
0.204
|
MACE
|
0.357
|
10
|
Metabolic syndrome
|
0.183
|
Hyperlipidemia
|
0.352
|
No
|
Keywords by
betweenscentrality
|
Score
|
Keyword by TF-IDF
|
Score
|
1
|
Atherosclerosis
|
0.109
|
Atrial fibrillation
|
42
|
2
|
CAD
|
0.103
|
Heart failure
|
38
|
3
|
Dyslipidemia
|
0.095
|
Breast cancer
|
37
|
4
|
Diabetes mellitus
|
0.067
|
Rheumatoid arthritis
|
37
|
5
|
CVD
|
0.062
|
Combined hyperlipidemia
|
36
|
6
|
Depression
|
0.056
|
Arrhythmias
|
35
|
7
|
Hypertension
|
0.050
|
Multiple sclerosis
|
31
|
8
|
Hypertriglyceridemia
|
0.030
|
NAFLD
|
30
|
9
|
CKD
|
0.028
|
Contrastnnduced AKI
|
27
|
10
|
Alzheimer Disease
|
0.028
|
Prostate cancer
|
27
|
ÇÏÀ§±¸Á¶ ÆľÇÀ» À§ÇÑ Ä¿¹Â´ÏƼ ºÐ¼®¿¡¼´Â ¸ðµâ¼º ÃÖÀû Àý´ÜÁ¡Àº 0.333Á¡À̾úÀ¸¸ç À̸¦ Àû¿ëÇÏ¿© ³×Æ®¿öÅ©¸¦ ÇÏÀ§±¸Á¶·Î ºÐ·ù ½Ã ÃÑ 17°³ÀÇ ÇÏÀ§±×·ìÀ¸·Î ºÐ·ùµÇ¾ú´Ù. À̵é Áß 2°³ ÀÌ»óÀÇ Å°¿öµåµéÀÌ Æ÷ÇÔµÈ ÇÏÀ§±×·ìÀº ÃÑ 5°³À̾ú´Ù(Figure 1). °¡Àå Å« ±×·ìÀº 13°³ÀÇ Å°¿öµå ·Î ±¸¼ºµÈ ±×·ì 17·Î ¾ÆÅä¹Ù½ºÅ¸Æ¾ÀÇ ÁÖ¿ä ÀûÀÀÁõÀÎ ÀÌ»óÁöÁúÇ÷Áõ, °í ÄÝ·¹½ºÅ×·ÑÇ÷Áõ, °íÁöÇ÷Áõ, °íÁß¼ºÁö¹æÇ÷Áõ, º¹ÇÕ °íÁöÇ÷Áõ(Combined hyperlipidemia), °¡Á·¼º º¹ÇÕ °íÁöÇ÷Áõ(Familial combined hyperlipid\-emia), ´ë»çÁõÈıº, ÀÚ°¡¸é¿ª±Ù¿°(Autoimmune myositis), ½ÅÁõÈıº(Nephrotic syndrome), ºñ¾ËÄݼº Áö¹æ°£¿°(Non-alcoholic fatty liver dis\-ease), ºñ¸¸(Obesity), ÃéÀå¿°(Pancreatitis) ¹× ·ù¸¶Æ¼½º°üÀý¿°(Rheuma\-toid arthritis)À¸·Î ±¸¼ºµÇ¾ú´Ù.
Ãâó : Á¤ÈÖ¼ö, °±æ¿ø, ÃÖ¿õ et al., ¾ÆÅä¹Ù½ºÅ¸Æ¾ÀÇ »õ·Î¿î ¾à¹° ÀûÀÀÁõ Ž»öÀ» À§ÇÑ ºñÁ¤Çü µ¥ÀÌÅÍ ºÐ¼® (2018).J Health Info Stat 2018;43(4):329-335